ArticleCancer cell2021
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05257551 (Tempus SCLC Observational Study), which is not on this map. Cited by 306 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
306citing papers in PubMed, 1 pooled it
25.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tempus SCLC Observational Study: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays
Who cites it
306 citing papers in PubMed, 1 synthesis or guideline pooled it, 408 citations in OpenAlex.
- Prognostic values and clinical significance of POU2F3 expression in neuroendocrine carcinomas: a meta-analysis with a focus on small cell lung cancer.Annals of medicine · 2025Pooled it
- Trial
- NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.The Journal of clinical investigation · 2025Trial
- High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy.International journal of cancer · 2026Article
- Macrophage- or neutrophil-expressed UPP1 drives tumor growth and immune suppression in the tumor microenvironment.Science advances · 2026Article
- Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report.JTO clinical and research reports · 2026Article
- A narrative review of barrier-matched engineering of macrophages for solid tumor immunotherapy: design logic, translational barriers and clinical outlook.Translational cancer research · 2026Review
- DONSON links tumor-cell survival to MIF-associated macrophage remodeling in small cell lung cancer.Apoptosis : an international journal on programmed cell death · 2026Article
- Article
- PAX5 modulates vascularization and contributes to neuroendocrine lineage transition during carcinoma progression.The Journal of clinical investigation · 2026Article
- CD55 organizes lipid raft-LCK signaling to potentiate NK-cell antitumor immunity.Cell research · 2026Article
- Article
- Review
- OX40 (TNFRSF4) Tracks Immune Infiltration in Small Cell Lung Cancer and Shows a Cohort-Specific, Non-Replicated Association with the POU2F3/SCLC-P Subtype: A Multi-Source In Silico Analysis.International journal of molecular sciences · 2026Article
- Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System.Endocrine pathology · 2026Review
- Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer.Cancer discovery · 2026Article
- Deciphering lung cancer at high resolution: a narrative review of applications of single-cell and spatial transcriptomics sequencing.Translational lung cancer research · 2026Review
- Proteomic Profiling Identifies CLDN3 as a Tumor-Selective Therapeutic Target in Small Cell Lung Cancer.bioRxiv : the preprint server for biology · 2026Article
- [Expert Consensus on Immunotherapy for Extensive-stage Small Cell Lung Cancer Based on Molecular Subtyping].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltration.Nature communications · 2026Article
246 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 5 institutions in 3 countries.
Joseph M ChanDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
Álvaro Quintanal-VillalongaDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Vianne Ran GaoProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; Weill Cornell Medical College, New York, NY 10065, USA.
Yubin XieProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; Weill Cornell Medical College, New York, NY 10065, USA.
Viola AllajDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ojasvi ChaudharyProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
Ignas MasilionisProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
Jacklynn EggerDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Andrew ChowDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Thomas WalleDepartment of Medical Oncology; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Clinical Cooperation Unit Virotherapy; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Marissa MattarAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Dig V K YarlagaddaProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
James L WangDepartment of Computer Science, Columbia University, New York, NY 10027, USA.
Fathema UddinDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Michael OffinDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Metamia CiampricottiDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Besnik QeriqiAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Amber BahrAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Umesh K BhanotPrecision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
W Victoria LaiDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Matthew J BottThoracic Service, Department of Surgery, Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
David R JonesThoracic Service, Department of Surgery, Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Arvin RuizDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Marina K BaineDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Yanyun LiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Natasha RekhtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
John T PoirierPerlmutter Cancer Center, New York University Langone Health, New York, NY 10065, USA.
Tal NawyProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
Triparna SenDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA.
Linas MazutisInstitute of Biotechnology, Vilnius University, Vilnius, Lithuania.
Travis J HollmannDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Dana Pe'erProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: peerster@gmail.com.
Charles M RudinDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: rudinc@mskcc.org.
Memorial Sloan Kettering Cancer Center · USColumbia University · USGerman Cancer Research Center · DENYU Langone Health · USVilnius University · LT
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MCoordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9MTransition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain MetastasisU2CCA233284 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PE'ER, DANA · 2018 to 2022
$12.9MTumor-specific T cell state dynamics and heterogeneity in early tumorigenesisU54CA209975 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LESLIE, CHRISTINA S, RUDENSKY, ALEXANDER Y · 2016 to 2021
$11.8MNovel therapeutic development for small cell lung cancerR35CA263816 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Charles M. Rudin · 2021 to 2026
$6.3MDeterminants of acquired resistance in small cell lung cancerR01CA197936 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RUDIN, CHARLES M. · 2016 to 2020
$3.1MBRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinomaR01CA217169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2018 to 2022
$2.5MTargeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinomaR01CA240472 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2019 to 2023
$2.4MExploring the combinatorial efficacy between chemotherapy and T cell checkpoint inhibition and the role of cellular senescenceK08CA245206 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BOTT, MATTHEW J · 2020 to 2024
$1.3MAssessment of Tim-4+ Pleural Macrophages as Negative Regulators of Anti-Tumor T Cell Immunity in Lung CancerK08CA248723 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHOW, ANDREW · 2020 to 2022
$602kNCI NIH HHS K08 CA245206NCI NIH HHS K08 CA248723NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA197936NCI NIH HHS R01 CA217169NCI NIH HHS R01 CA240472NCI NIH HHS R35 CA263816NCI NIH HHS U24 CA213274NCI NIH HHS U2C CA233284NCI NIH HHS U54 CA209975
Abstract
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define the heterogeneity of tumors and their associated microenvironments across subtypes, we sequenced 155,098 transcriptomes from 21 human biospecimens, including 54,523 SCLC transcriptomes. We observe greater tumor diversity in SCLC than lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes. We discover a PLCG2-high SCLC phenotype with stem-like, pro-metastatic features that recurs across subtypes and predicts worse overall survival. SCLC exhibits greater immune sequestration and less immune infiltration than lung adenocarcinoma, and SCLC-N shows less immune infiltrate and greater T cell dysfunction than SCLC-A. We identify a profibrotic, immunosuppressive monocyte/macrophage population in SCLC tumors that is particularly associated with the recurrent, PLCG2-high subpopulation.
Indexed as
Cell PlasticityGene Expression ProfilingHumansLung NeoplasmsNeoplasm MetastasisPhospholipase C gammaPrognosisSequence Analysis, RNASingle-Cell AnalysisSmall Cell Lung CarcinomaSurvival AnalysisPhospholipase C gammaPLCG2 protein, humanmetastasismyeloidPLCG2SCLCscRNA-seqsingle celltumor atlas
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05257551ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.